reach menopause at a mean age of 51 years, with 95% reaching menopause between 45 and 55 years. 1 Many cancer survivors experience menopausal symptoms without meeting the definition of menopause, including female survivors on aromatase inhibitors or
Search Results
Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass, and Nicole R. McMillian
Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas, and Catherine H. Van Poznak
N Coleman R . Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole . Oncologist 2008 ; 13 : 503 – 514 . 56 Gnant
William Gradishar and Kilian E. Salerno
%, and 68% of patients, respectively. 1 “Adjuvant endocrine therapy is a rational approach,” he said. “While this is mainly used in postmenopausal women, you can treat premenopausal women with aromatase inhibitors [AIs] as long as you render them
Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak
with a family history of fractures, body weight less than 70 kg, and prior nontraumatic fracture, and those of any age who are postmenopausal receiving aromatase inhibitor (AI) therapy, and those who are premenopausal with therapy-induced ovarian
Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force
predictive factors? Can certain subsets of premenopausal women with ER-positive tumors be adequately treated using tamoxifen and/or ovarian suppression and forego adjuvant chemotherapy? What is the optimal strategy for using aromatase inhibitors (AIs) in the
Josh Lauring, Ben Ho Park, and Antonio C. Wolff
cell lines and resensitize these cells to hormonal therapies, including tamoxifen and aromatase inhibitors. 20 , 23 , 25 - 28 In contrast, other studies have not found an increased sensitivity of LTED cells to dual PI3-kinase/mTOR inhibitors, and LTED
Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak
-induced ovarian failure must be carefully distinguished from menopause, because adjuvant use of aromatase inhibitors is only indicated in the absence of ovarian estrogen production. Bisphosphonate therapy can attenuate the bone loss associated with ovarian failure
Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Avinash Kambadakone, Casey Stein, Maxwell R. Lloyd, Megan Yuen, Laura M. Spring, Dejan Juric, Irene Kuter, Ioannis Sanidas, Beverly Moy, Therese Mulvey, Neelima Vidula, Nicholas J. Dyson, Leif W. Ellisen, Steven Isakoff, Nikhil Wagle, Adam Brufsky, Kevin Kalinsky, Cynthia X. Ma, Joyce O’Shaughnessy, and Aditya Bardia
. Clinical Parameters Abemaciclib Use After Prior CDK4/6i Therapy Given the lack of guidance from prospective randomized trials, practice patterns differed among physicians. Most patients received palbociclib in combination with an aromatase inhibitor (AI; n
William J. Gradishar
advanced breast cancer after disease progression on nonsteroidal aromatase inhibitors (AIs). 3 - 5 For instance, the phase III SoFEA trial revealed that combining fulvestrant with exemestane was no better than either fulvestrant alone or exemestane alone
